Literature DB >> 21931363

Acute coronary syndromes: Lackluster RUBY is received with some disappointment.

Bryony M Mearns.   

Abstract

Entities:  

Year:  2011        PMID： 21931363     DOI： 10.1038/nrcardio.2011.145

Source DB:  PubMed          Journal:  Nat Rev Cardiol        ISSN： 1759-5002            Impact factor:   32.419


× No keyword cloud information.
  1 in total

1.  RUBY-1: a randomized, double-blind, placebo-controlled trial of the safety and tolerability of the novel oral factor Xa inhibitor darexaban (YM150) following acute coronary syndrome.

Authors:  Ph Gabriel Steg; Shamir R Mehta; J Wouter Jukema; Gregory Y H Lip; C Michael Gibson; Frantisek Kovar; Petr Kala; Alberto Garcia-Hernandez; Ronny W Renfurm; Christopher B Granger
Journal:  Eur Heart J       Date:  2011-08-30       Impact factor: 29.983
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.